[1] |
Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012[J]. CA Cancer J Clin, 2015, 65(2): 87-108.
|
[2] |
Diaz de Leon A, Costa D, Pedrosa I. Role of multiparametric mr imaging in malignancies of the urogenital tract[J]. Magn Reson Imaging Clin N Am, 2016, 24(1): 187-204.
|
[3] |
冼土增,张俊夫,罗飞, 等. 多参数磁共振成像联合四基因模型提高前列腺癌早期诊断效能的临床研究[J/CD]. 中华腔镜泌尿外科杂志(电子版), 2018, 12(3): 149-153.
|
[4] |
Zhang K, Bangma CH, Roobol MJ. Prostate cancer screening in Europe and Asia[J]. Asian J Urol, 2017, 4(2): 86-95.
|
[5] |
Wong MC, Goggins WB, Wang HH, et al. Global incidence and mortality for prostate cancer: analysis of temporal patterns and trends in 36 countries[J]. Eur Urol, 2016, 70(5): 862-874.
|
[6] |
Center MM, Jemal A, Lortet-Tieulent J, et al. International variation in prostate cancer incidence and mortality rates[J]. Eur Urol, 2012, 61(6): 1079-1092.
|
[7] |
Barentsz JO, Richenberg J, Clements R, et al. ESUR prostate MR guidelines 2012[J]. Eur Radiol, 2012, 22(4): 746-757.
|
[8] |
Schoots IG, Roobol MJ, Nieboer D, et al. Magnetic resonance imaging-targeted biopsy may enhance the diagnostic accuracy of significant prostate cancer detection compared to standard transrectal ultrasound-guided biopsy: a systematic review and meta-analysis[J]. Eur Urol, 2015, 68(3): 438-450.
|
[9] |
Wysock JS, Mendhiratta N, Zattoni F, et al. Predictive value of negative 3T multiparametric magnetic resonance imaging of the prostate on 12-core biopsy results[J]. BJU Int, 2016, 118(4): 515-520.
|
[10] |
Pokorny MR, de Rooij M, Duncan E, et al. Prospective study of diagnostic accuracy comparing prostate cancer detection by transrectal ultrasound-guided biopsy versus magnetic resonance (MR) imaging with subsequent MR-guided biopsy in men without previous prostate biopsies[J]. Eur Urol, 2014, 66(1): 22-29.
|
[11] |
Haffner J, Lemaitre L, Puech P, et al. Role of magnetic resonance imaging before initial biopsy: comparison of magnetic resonance imaging-targeted and systematic biopsy for significant prostate cancer detection[J]. BJU Int, 2011, 108(8 Pt 2): E171-178.
|
[12] |
Schröder FH, Hugosson J, Roobol MJ, et al, Screening and prostate-cancer mortality in a randomized European study[J]. N Engl J Med, 2009, 360(13): 1320-1328.
|
[13] |
Schroder FH, Hugosson J, Roobol MJ, et al. Prostate-cancer mortality at 11 years of follow-up[J]. N Engl J Med, 2012, 366(11): 981-990.
|
[14] |
Schröder FH, Hugosson J, Roobol MJ. Roobol, et al. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up[J]. Lancet, 2014, 384(9959): 2027-2035.
|
[15] |
Wegelin O, van Melick HHE, Hooft L, et al. Comparing three different techniques for magnetic resonance imaging-targeted prostate biopsies: a systematic review of in-bore versus magnetic resonance imaging-transrectal ultrasound fusion versus cognitive registration. Is There a Preferred Technique? [J]. Eur Urol, 2017, 71(4): 517-531.
|
[16] |
Chen R, Ren S, Yiu MK, et al. Prostate cancer in Asia: A collaborative report[J]. Asian J Urol, 2014, 1(1): 15-29.
|
[17] |
Ito K. Prostate cancer in Asian men[J]. Nat Rev Urol, 2014,11(4): 197-212.
|